Table 2 Overview on clinical trials of hematological malignancies treated with DNA repair inhibitors
Target | Conditions | Compound | Phases | Participants | Status | NCT Number |
|---|---|---|---|---|---|---|
PAPR | Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB) | PARP Inhibitors | – | 178 | Completed | NCT04326023 |
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia | Veliparib (ABT-888) Temozolomide | Phase 1 | 66 | Active, not recruiting | NCT01139970 | |
Acute Myeloid Leukemia Recurrent Myelodysplastic Syndrome | Olaparib | Phase 2 | 94 | Recruiting | NCT03953898 | |
Leukemia Lymphoma | veliparib | Phase 1 | 23 | Completed | NCT00387608 | |
Chronic Lymphocytic Leukemia T-cell-prolymphocytic Leukemia | Niraparib (MK4827) | Phase 1 | 113 | Completed | NCT00749502 | |
Acute Myeloid Leukemia Myelodysplastic Syndrome Chronic Lymphocytic Leukemia Mantle Cell Lymphoma | BMN-673 (talazoparib) | Phase 1 | 33 | Completed | NCT01399840 | |
Leukemia | BMN 673 | Phase 1 | 12 | Recruiting | NCT03974217 | |
Acute Myeloid Leukemia | BMN 673 Decitabine | Phase 1 Phase 2 | 25 | Active, not recruiting | NCT02878785 | |
B-cell Malignancy, Low-grade | E7449 (dual PARP1/2 and TNKS1/2 inhibitor) alone E7449 plus TMZ E7449 plus carboplatin and paclitaxel | Phase 1 Phase 2 | 41 | Completed | NCT01618136 | |
Adult Acute Megakaryoblastic Leukemia Adult Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia Essential Thrombocythemia Myelodysplastic Syndrome Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia Polycythemia Vera Recurrent Adult Acute Lymphoblastic Leukemia | Veliparib Topotecan-Hydrochloride Carboplatin | Phase 1 | 12 | Active, not recruiting | NCT00588991 | |
Acute Myeloid Leukemia Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative| Chronic Myelomonocytic Leukemia| Essential Thrombocythemia| Myelodysplastic/Myeloproliferative Neoplasm| Myelofibrosis| Polycythemia Vera| | Veliparib Topotecan-Hydrochloride Carboplatin | Phase 2 | 60 | Suspended | NCT03289910 | |
Leukemia| Lymphoma| Waldenstrom Macroglobulinemia| | Veliparib Rituximab Bendamustine- Hydrochloride | Phase 1 Phase 2 | 43 | Completed | NCT01326702 | |
Mantle Cell Lymphoma | CEP-9722 Gemcitabine Cisplatin | Phase 1 | 24 | Completed | NCT01345357 | |
DNA-PK | Chronic Lymphocytic Leukemia | CC-115 | Phase 1 | 118 | Completed | NCT01353625 |
Refractory/Recurrent Acute Myeloid Leukemia | MSC2490484A (M3814) Mitoxantrone Etoposide Cytarabine | Phase 1 | 48 | Recruiting | NCT03983824 | |
Chronic Lymphocytic Leukemia | MSC2490484A (M3814) | Phase 1 | 31 | Completed | NCT02316197 | |
Lymphoma, Non-Hodgkin | CC-122 (Avadomide) | Phase 1 | 15 | Active, not recruiting | NCT02509039 | |
Large B-Cell, Diffuse Lymphoma, Non-Hodgkin | CC-122 Obinutuzumab | Phase 1 | 75 | Active, not recruiting | NCT02417285 | |
Diffuse B-Cell Lymphoma | CC-122 RCHOP | Phase 1 | 35 | Completed | NCT03283202 | |
Leukemia, Lymphocytic, Chronic, B-Cell | CC-122 Ibrutinib Obinutuzumab | Phase 1 Phase 2 | 47 | Completed | NCT02406742 | |
Multiple Myeloma Lymphoma, Large B-Cell, Diffuse | CC-122 | Phase 1 | 271 | Active, not recruiting | NCT01421524 | |
Lymphoma, Large B-Cell, Diffuse | CC-122 CC-223 Rituximab CC-292 | Phase 1 | 174 | Active, not recruiting | NCT02031419 | |
Lymphoma, Non-Hodgkin Lymphoma, Large B-Cell, Diffuse Lymphoma, Follicular | CC-122 JCAR017 Durvalumab Ibrutinib CC-220 Relatlimab Nivolumab CC-99282 | Phase 1 Phase 2 | 77 | Recruiting | NCT03310619 | |
Chronic Lymphoproliferative Diseases | GRN163L (Imetelstat) | Phase 1 | 48 | Completed | NCT00124189 | |
Multiple Myeloma | GRN163L | Phase 1 | 40 | Completed | NCT00718601 | |
Multiple Myeloma | GRN163L | Phase 1 | 20 | Completed | NCT00594126 | |
Primary Myelofibrosis Secondary Myelofibrosis Myeloid Malignancies | GRN163L | Phase 2 | 81 | Completed | NCT01731951 | |
Myelofibrosis (JAK-Inhibitor Treatment resistance) | GRN163L Best Available Therapy (BAT) | Phase 3 | 320 | Recruiting | NCT04576156 | |
Myelodysplastic Syndromes | GRN163L Placebo | Phase 2 Phase 3 | 225 | Recruiting | NCT02598661 | |
Multiple Myeloma | GRN163L lenalidomide | Phase 2 | 13 | Completed | NCT01242930 | |
Essential Thrombocythemia| Polycythemia Vera | GRN163L | Phase 2 | 20 | Completed | NCT01243073 | |
ATR | Lymphomas | BAY1895344 | Phase 1 | 241 | Recruiting | NCT03188965 |
11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL)| Prolymphocytic Leukaemia (PLL)| B Cell Lymphomas | AZD6738 (Ceralasertib) | Phase 1 | 2 | Completed | NCT01955668 | |
Leukemia| Myelodysplastic Syndrome CMML | AZD6738 | Phase 1 | 52 | Recruiting | NCT03770429 | |
Chronic Lymphocytic Leukemia | AZD6738 Acalabrutinib | Phase 1 Phase 2 | 12 | Active, not recruiting | NCT03328273 | |
Cancers | AZD6738 Gemcitabine | Phase 1 | 55 | Recruiting | NCT03669601 | |
Relapsed/refractory aggressive Non-Hodgkin's Lymphoma | AZD6738 AZD9150 Acalabrutinib Hu5F9-G4 Rituximab AZD5153 | Phase 1 | 30 | Completed | NCT03527147 |